300 related articles for article (PubMed ID: 28523537)
1. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M; Souteiro P; Carvalho D
Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
3. Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
Ji MJ; Kim JH; Lee JH; Lee JH; Kim YH; Paek SH; Shin CS; Kim SY
Pituitary; 2017 Oct; 20(5):578-584. PubMed ID: 28710724
[TBL] [Abstract][Full Text] [Related]
4. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
5. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Biswas M; Smith J; Jadon D; McEwan P; Rees DA; Evans LM; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2005 Jul; 63(1):26-31. PubMed ID: 15963057
[TBL] [Abstract][Full Text] [Related]
6. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
Anagnostis P; Adamidou F; Polyzos SA; Efstathiadou Z; Karathanassi E; Kita M
Pituitary; 2012 Mar; 15(1):25-9. PubMed ID: 21409614
[TBL] [Abstract][Full Text] [Related]
7. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal.
Huda MS; Athauda NB; Teh MM; Carroll PV; Powrie JK
Clin Endocrinol (Oxf); 2010 Apr; 72(4):507-11. PubMed ID: 19549247
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
10. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
13. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
14. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal.
Watanabe S; Akutsu H; Takano S; Yamamoto T; Ishikawa E; Suzuki H; Matsumura A
Clin Endocrinol (Oxf); 2017 Feb; 86(2):207-213. PubMed ID: 27651307
[TBL] [Abstract][Full Text] [Related]
15. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
16. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
[TBL] [Abstract][Full Text] [Related]
17. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
18. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
19. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]